Rival drugmakers launch joint trial of medicines for COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
August 5, 2020 6:39 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $7.16, $1.18 better than the analyst estimate of $5.98. Revenue for the quarter came in at $1.95 billion versus the consensus estimate of $1.74 billion.
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4)
Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion
Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million
